BTAI

BIOXCEL THERAPEUTICS INC

BTAI·09075P204·US·Common Stock·Healthcare - Drug Manufacturers - Specialty & Generic-13D/G

BTAI (BIOXCEL THERAPEUTICS INC) is held by 32 institutional investors as of Q2 2026. Largest holders: MILLENNIUM MANAGEMENT LLC ($3M), OAKTREE CAPITAL MANAGEMENT LP ($1.9M), VANGUARD CAPITAL MANAGEMENT LLC ($1.3M). Net institutional sentiment: Bullish.

32
Holders
(2 Elite)
$8.2M
Total Value
81% (21)
Consensus
17 buying - 4 selling
13F: Insider & Congress: Updated regularly
BTAI

Smart Money Verdict

View all
Loading verdict
Held by 32 funds
2 elite

Who's Trading

Source dates: Price Aug 27, 2026 · Insiders May 7, 2026 · Activists Aug 14, 2026 · Congress none

ActivistARArmistice Capital, LLC5.0%Aug 14, 2026
ActivistARArmistice Capital, LLC7.0%May 15, 2026
InsiderRJRodriguez JavierExercise 9K shMay 1, 2026
Checking access…

Top Holders

Checking access…
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
Increased
2.1M(+9.2%)$3M0.0%-62.01%
29
Increased
1.4M(+472.3%)$1.9M0.0%-47.04%
42
Increased
919,545(+343.5%)$1.3M0.0%-46.31%
28
Increased
242,251(+5.3%)$341,9110.0%-97.27%
17
Increased
179,433(+112.9%)$253,0010.0%-66.08%
25
Increased
158,065(+199.4%)$222,8710.0%-72.12%
25
New
149,220$210,4000.0%-44.68%
35
Increased
136,937(+61.3%)$193,0810.0%-48.95%
22
Unchanged
92,118$129,8860.0%-64.15%
0
Unchanged
90,300$127,3230.0%-70.23%
0
Increased
83,588(+3.4%)$117,8590.0%-51.06%
23
Decreased
63,139(-52.1%)$82,7120.0%-52.86%
0
Increased
56,318(+55.1%)$79,4080.0%-64.20%
21
Unchanged
41,000$57,8100.0%-60.01%
0
New
38,038$53,6340.0%-44.68%
29
New
17,200$24,2520.0%-44.68%
29
Unchanged
16,214$22,8600.0%-83.13%
0
Increased
4,337(+0.4%)$6,1150.0%-96.51%
11
New
2,998$4,2270.0%-44.68%
22
Decreased
1,671(-84.2%)$2,3560.0%-81.06%
0

Showing 1-20 of 33

1 / 2
BTAIBTAIBIOXCEL THERAPEUTICS INC

Other Healthcare stocks held by institutions

Data sourced from four public-disclosure sources: SEC 13F, Form 4, 13D/13G, and House/Senate STOCK Act disclosures. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used